Evolent Health Sees Q3 2024 Revenue $615M - $635M Vs $636.44M Est.; Sees FY24 $2.56B - $2.6B Vs $2.58B Est.
Portfolio Pulse from Benzinga Newsdesk
Evolent Health has provided its Q3 2024 revenue guidance in the range of $615M to $635M, which is slightly below the estimated $636.44M. For the full fiscal year 2024, the company expects revenue between $2.56B and $2.6B, aligning closely with the estimated $2.58B.
August 08, 2024 | 8:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Evolent Health's Q3 2024 revenue guidance of $615M to $635M is slightly below the estimated $636.44M, which may cause short-term negative sentiment. However, the FY24 revenue guidance of $2.56B to $2.6B aligns closely with the $2.58B estimate, potentially mitigating some concerns.
The Q3 2024 revenue guidance being slightly below estimates may lead to short-term negative sentiment among investors. However, the full-year guidance aligns closely with expectations, which could mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100